AMP-activated Protein Kinase α2 Subunit Is Required for the Preservation of Hepatic Insulin Sensitivity by n-3 Polyunsaturated Fatty Acids

Tomas Jelenik,1 Martin Rossmeisl,1 Ondrej Kuda,1 Zuzana Macek Jilkova,1 Dasa Medrikova,1 Vladimir Kus,1 Michal Hensler,1 Petra Janovska,1 Ivan Miksik,2 Marcin Baranowski,3 Jan Gorski,3 Sophie Hébrard,4,5 Thomas E. Jensen,6 Pavel Flachs,1 Simon Hawley,7 Benoit Viollet,4,5 and Jan Kopecky1

OBJECTIVE—The induction of obesity, dyslipidemia, and insulin resistance by high-fat diet in rodents can be prevented by n-3 long-chain polyunsaturated fatty acids (LC-PUFAs). We tested a hypothesis whether AMP-activated protein kinase (AMPK) has a role in the beneficial effects of n-3 LC-PUFAs.

RESEARCH DESIGN AND METHODS—Mice with a whole-body deletion of the α2 catalytic subunit of AMPK (AMPKα2−/−) and their wild-type littermates were fed on either a low-fat chow, or a corn oil-based high-fat diet (cHF), or a chHF diet with 15% lipids replaced by n-3 LC-PUFA concentrate (chHF+F).

RESULTS—Feeding a chHF diet induced obesity, dyslipidemia, and whole-body insulin resistance in mice of both genotypes. Although chHF+F feeding increased hepatic AMPKα2 activity, the body weight gain, dyslipidemia, and the accumulation of hepatic triglycerides were prevented by the chHF+F diet to a similar degree in both AMPKα2−/− and wild-type mice in ad libitum-fed state. However, preservation of hepatic insulin sensitivity by n-3 LC-PUFAs required functional AMPKα2 and correlated with the induction of adiponectin and reduction in liver diacylglycerol content. Under hyperinsulinemic-euglycemic conditions, AMPKα2 was essential for preserving low levels of both hepatic and plasma triglycerides, as well as plasma free fatty acids, in response to the n-3 LC-PUFA treatment.

CONCLUSIONS—Our results show that n-3 LC-PUFAs prevent hepatic insulin resistance in an AMPKα2-dependent manner and support the role of adiponectin and hepatic diacylglycerols in the regulation of insulin sensitivity. AMPKα2 is also essential for hypolipidemic and antisteatotic effects of n-3 LC-PUFA under insulin-stimulated conditions. Diabetes 59:2737–2746, 2010

© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
energy levels, namely, the partitioning between lipid oxidation and lipogenesis (29,30).

We hypothesized that the effects of n-3 LC-PUFA on insulin sensitivity and lipid metabolism in mice fed an obesogenic high-fat diet require a functional AMPKα2 isoform. To test this hypothesis in vivo, AMPKα2−/− and wild-type mice were fed either a low-fat chow diet (Chow), a corn oil-based high-fat (cHF) diet, or cHF diet in which 15% of the lipids were replaced by n-3 LC-PUFA concentrate (cHF+F). Our results demonstrate an AMPKα2-dependent action of n-3 LC-PUFAs, in 1) the preservation of hepatic and muscle insulin sensitivity; 2) the changes in hepatic diacylglycerol content and composition; and 3) the antisteatotic effect in the liver and hypolipidemic effect under insulin-stimulated conditions, such as during hyperinsulinemic-euglycemic clamp, but not when the organism depends on lipids as substrates.

RESEARCH DESIGN AND METHODS

Four-month-old whole-body AMPKα2−/− (29) backcrossed to C57BL/6J mice for nine generations, and wild-type littermate controls were fed on either Chow, cHF, or cHF+F diet for nine weeks. Body weight and food consumption were recorded, and EDTA-plasma and tissues were collected for various analyses as described in the online appendix, available at http://diabetes.diabetesjournals.org. Male mice were used for all the experiments, except for the measurements of hepatic AMPK activity, which were performed on female mice. The experiments were conducted under the guidelines for the use and care of laboratory animals of the Institute of Physiology and followed the “Principles of laboratory animal care” (National Institutes of Health publication no. 85-23, revised 1985).

Blood and plasma parameters. Blood glucose was measured using calibrated glucometers (LifeScan, Milpitas, CA). Nonesterified fatty acids (NEFAs), triglycerides, and total cholesterol were determined in plasma using the following enzymatic photometric tests: NEFA-C (Wako Chemicals, Neuss, Germany), triacylglycerols liquid, and cholesterol liquid (Pliva-Lachema Diagnostika, Brno, Czech Republic), respectively. Plasma insulin was measured using the Sensitive Rat Insulin RIA Kit (LINCO Research, St. Charles, MO). Total adiponectin levels and adiponectin multimeric complexes were determined using Western blotting (31).

Lipid content and gene expression in the liver. The tissue content of triglycerides was estimated in ethanolic KOH tissue lysates as described before (8). The content and fatty acid composition of the phospholipid, diacylglycerol, triglyceride, and ceramide fractions were assessed in tissue lipid extracts; gene expression was evaluated using real-time RT-PCR (see online appendix).

Activity of α1 and α2 AMPK isofoms. Livers were collected by freeze-clamping (LifeScan, Milpitas, CA). Liver cytosol was immunoprecipitated from tissue extracts, and the activity was assayed using a peptide substrate (42); see the online appendix.

Hyperinsulinemic-euglycemic clamp. Five days before the experiment, an indwelling catheter was placed into the left femoral vein under anesthesia (33). Mice were allowed to recover for 5–7 days, followed by a 6-h fast (8:00 a.m.–2:00 p.m.) prior to the experiment. The whole-body glucose turnover was determined under basal (nonstimulated) and insulin-stimulated conditions (hyperinsulinemic-euglycemic clamp), using separate groups of mice. Insulin (Actrapid, Novo Nordisk Pharma, Denmark) was infused at a constant rate of 4.8 mU/kg/min for 3 h, while D-[3-14C]glucose (Perkin Elmer, Boston, MA) was infused at a rate of 15.9 kBq/min. Throughout the infusion, glucose concentration and D-[3-14C]glucose specific activity (during the last hour of infusion) were determined in tail blood. Euglycemia (~5.55 mmol/L) was maintained by periodically adjusting a variable infusion of 33% glucose (35). At the end of a 3-h infusion period, mice were first anesthetized by diethyl ether, exsanguinated through the cervical incision, and then killed by cervical dislocation, and tissues (liver and quadriceps muscle) and EDTA-plasma were collected for biochemical analyses (see supplementary Table 1 and Research Design and Methods of the online appendix for details on basic clamp parameters and methodology).

Primary cultures of hepatocytes. Hepatocytes were isolated from livers of fed mice by a modification of the collagenase method (34) and seeded at a density of 0.5 × 10⁶ cells per each 35-mm Petri dish. Rates of basal and insulin-stimulated de novo lipogenesis and AICAR-stimulated fatty acid oxidation were measured using [1-14C]acetate and [1-14C]palmitate, respectively (see online appendix).

RESULTS

Enhancement of hepatic AMPKα2 activity by n-3 LC-PUFAs. Specific activities of AMPKα1 and AMPKα2 were evaluated in the liver of ad libitum-fed mice after nine weeks of the differential dietary treatment (Fig. 1). No significant effect of either diet (Chow, cHF, and cHF+F) or genotype (wild-type versus AMPKα2−/−) on AMPKα1-specific activity was observed, although the AMPKα1 activity tended to be higher in the AMPKα2−/− mice (Fig. 1A). In contrast, AMPKα2 activity was stimulated by n-3 LC-PUFAs (cHF+F diet; Fig. 1B). AMPKα2 activity was not detected in the AMPKα2−/− mice (Fig. 1B). No changes were detected in the activity of AMPKα1 and AMPKα2 in the quadriceps muscle in response to n-3 LC-PUFAs (not shown).

AMPKα2 is not required for antiobesity and hypolipidemic effects of n-3 LC-PUFAs in ad libitum-fed mice. At four months of age, at the beginning of dietary treatments, wild-type and AMPKα2−/− mice fed the Chow diet exhibited similar body weights (Table 1). In mice of both genotypes, cHF-feeding for nine weeks resulted in greater body weight gain compared with the Chow-fed mice. However, this effect was less pronounced in AMPKα2−/− mice fed mice by a modification of the collagenase method (34) and seeded at a density of 0.5 × 10⁶ cells per each 35-mm Petri dish. Rates of basal and insulin-stimulated de novo lipogenesis and AICAR-stimulated fatty acid oxidation were measured using [1-14C]acetate and [1-14C]palmitate, respectively (see online appendix).

FIG. 1. Liver AMPKα1 (A) and AMPKα2 (B) activity in wild-type and AMPKα2−/− mice fed either a Chow diet, cHF, or cHF+F for 9 weeks. The data are the means ± SE (n = 5–8). In the AMPKα2−/− mice, AMPKα2 activity was below the detection limit. *P < 0.05 versus genotype Chow; †P < 0.05 versus genotype cHF.

Statistics. All values are presented as means ± SE. Data were analyzed by two-way ANOVA. Comparisons were judged to be significant at P ≤ 0.05.
mice (Table 1). In both wild-type and AMPKα2−/− mice, the chF+ diet induced smaller body weight gain than the chF diet (Table 1 and supplementary Figure 1). None of the differences in body weight gain could be explained by caloric intake, which was similar in all experimental groups (Table 1). The weight of fat depots increased in response to chF feeding, while the chF+ diet partially prevented this increase (Table 1). Triglycerides and NEFA levels were strongly increased in Chow- and chF-fed mice, while cholesterol levels were markedly and significantly elevated by the chF diet. n-3 LC-PUFAs lowered plasma lipid levels independently of AMPKα2. Triglycerides and NEFA levels were strongly reduced, even below the levels observed in the Chow-fed mice (Table 1).

### AMPKα2 is essential for the preservation of insulin sensitivity in response to n-3 LC-PUFAs.

After nine weeks of dietary treatment, no change was observed in blood glucose, but elevations were observed in plasma insulin levels in response to the chF diet in ad libitum-fed mice of both genotypes. However, the increase in plasma insulin levels was less pronounced in AMPKα2−/− mice, closely reflecting the genotype-dependent differences in body weight gain (Table 1). A similar pattern of changes in insulin levels was also observed in fasted mice, in which n-3 LC-PUFAs significantly reduced insulin levels only in wild-type animals (Table 1). As expected, plasma levels of total as well as high molecular weight form of adiponectin, an adipokine associated with increased insulin sensitivity (35), were increased ~1.4- and ~1.2-fold, respectively, in wild-type mice in response to n-3 LC-PUFA supplementation (Table 1 and supplementary Fig. 2, available in an online appendix); however, no significant increase of plasma adiponectin by n-3 LC-PUFAs was observed in AMPKα2−/− mice.

In further experiments, hyperinsulinemic-euglycemic clamps were performed to evaluate whole-body insulin sensitivity. Under basal conditions, glucose turnover rate (GTO; i.e., glucose uptake in peripheral tissues) was similar in all groups of mice (supplementary Table 1). Under insulin-stimulated conditions (Fig. 2A–F), the amount of exogenous glucose required to maintain euglycemia during the clamp, i.e., the glucose infusion rate (GIR), was ~1.3-fold lower in AMPKα2−/− than in wild-type mice fed the Chow diet (Fig. 2A). On the other hand, GIR was decreased by the chF diet to a similar level in mice of both genotypes, manifesting diet-induced insulin resistance. This was attributed to a decreased GTO and, in particular, to an impaired suppression of hepatic glucose production (HGP) by insulin, with HGP being ~8.5-fold higher in the chF+ diet compared with the Chow-fed wild-type mice (Fig. 2C). In wild-type mice, chF+F diet feeding increased GIR and GTO (~1.9- and ~1.2-fold increase, respectively) as compared with chF-fed mice, while HGP was lowered to a similar level as in the Chow-fed mice. These results document the protective effects of n-3 LC-PUFAs from high-fat diet-induced insulin resistance in wild-type mice, namely, at the level of HGP. In contrast, none of these beneficial effects of n-3 LC-PUFAs was observed in AMPKα2−/− mice, in which neither the GIR (Fig. 2A) nor the GTO (Fig. 2B) differed between the chF+ diet and the chF-fed mice, whereas the rate of HGP was even higher in the chF+F-fed than in the chF-fed AMPKα2−/− mice (Fig. 2C). Although whole-body glycolysis was similar in all the groups (Fig. 2D), the rate of whole-body glycogen synthesis, which reflects insulin sensitivity of muscle glucose metabolism, was dependent on both diet and genotype (Fig. 2E). In the Chow-fed mice, the rate of whole-body glycogen synthesis tended to be higher in wild-type mice than in AMPKα2−/− mice. Only in the former mice was it significantly affected by dietary treatment. Thus, in wild-type mice, glycogen synthesis was

### Table 1

| Metabolic parameters | Chow | chF | chF+F | Chow | chF | chF+F |
|----------------------|------|-----|-------|------|-----|-------|
| Food consumption (kJ/g · day) | 2.0 ± 0.1 | 1.8 ± 0.1 | 1.9 ± 0.0 | 2.0 ± 0.1 | 1.8 ± 0.1 | 2.0 ± 0.1 |
| Initial body weight (g) | 27.8 ± 0.5 | 27.9 ± 0.5 | 27.7 ± 0.5 | 27.1 ± 0.3 | 27.7 ± 0.4 | 27.3 ± 0.4 |
| Body weight gain (g) | 1.4 ± 0.2 | 7.0 ± 1.1* | 2.8 ± 0.7† | 1.8 ± 0.3 | 4.6 ± 0.7*‡ | 1.2 ± 0.4† |
| Adiposity | | | | | | |
| Epididymal AT (g) | 0.43 ± 0.02 | 1.52 ± 0.19* | 1.12 ± 0.14** | 0.37 ± 0.03 | 1.19 ± 0.16*** | 0.64 ± 0.07****††† |
| Subcutaneous AT (g) | 0.20 ± 0.01 | 0.54 ± 0.05* | 0.42 ± 0.04†† | 0.17 ± 0.01 | 0.34 ± 0.03‡‡ | 0.23 ± 0.01‡‡‡ |
| Epididymal adipocytes size (μm²) | ND | 15,971 ± 1,784 | 10,232 ± 185§ | ND | 13,298 ± 1,632 | 8,593 ± 896§ |
| Subcutaneous adipocytes size (μm²) | 2,916 ± 610 | 6,775 ± 1,718* | 7,311 ± 1,308* | 3,395 ± 139 | 6,625 ± 926* | 5,432 ± 648* |
| Plasma metabolites | | | | | | |
| Triglycerides (mmol/l) | 1.17 ± 0.08 | 1.23 ± 0.11 | 0.62 ± 0.07†† | 1.04 ± 0.06 | 1.22 ± 0.08 | 0.73 ± 0.06‡‡ |
| NEFAs (mmol/l) | 0.90 ± 0.05 | 0.94 ± 0.05 | 0.59 ± 0.04†† | 0.88 ± 0.04 | 0.99 ± 0.06 | 0.68 ± 0.04‡‡ |
| Cholesterol (mmol/l) | 2.25 ± 0.08 | 4.12 ± 0.25* | 3.10 ± 0.20† | 2.10 ± 0.06 | 3.94 ± 0.18* | 2.75 ± 0.14* |
| Glucose (mmol/l) | 9.9 ± 0.4 | 10.7 ± 0.5 | 10.4 ± 0.3 | 9.7 ± 0.4 | 10.0 ± 0.4 | 9.4 ± 0.4 |
| Plasma hormones | | | | | | |
| Insulin fed (ng/ml) | 0.66 ± 0.11 | 1.73 ± 0.29* | 1.47 ± 0.28* | 0.60 ± 0.07 | 1.34 ± 0.20* | 0.95 ± 0.12* |
| Insulin fasted (ng/ml) | 0.13 ± 0.01 | 0.39 ± 0.06* | 0.19 ± 0.05† | 0.16 ± 0.02 | 0.22 ± 0.03‡ | 0.15 ± 0.01 |
| Total adiponectin (A.U.) | 1.15 ± 0.09 | 0.97 ± 0.10 | 1.33 ± 0.09§ | 0.82 ± 0.09‡‡ | 0.80 ± 0.07 | 0.97 ± 0.08§ |
| HMW: total adiponectin | 0.38 ± 0.02 | 0.36 ± 0.02 | 0.44 ± 0.02‡ | 0.55 ± 0.02 | 0.34 ± 0.02 | 0.39 ± 0.02 |

Data are means ± SE of 27–30 mice for metabolic parameters and 13–15 mice for other measures. AMPKα2−/− and wild-type mice were fed either a Chow diet, chF, or chF+F for nine weeks. Food consumption was measured weekly for nine weeks. Body weight gain (see supplementary Fig. 1) and plasma parameters were assessed in all ad libitum-fed mice after nine weeks. Plasma insulin levels were also assessed in fasted mice after eight weeks. AT, adipose tissue; A.U., arbitrary units; HMW, total adiponectin, ratio of high molecular weight to total adiponectin (for levels of all molecular weight forms of adiponectin; ND, no data; see supplementary Figure 2); †P < 0.05 vs. genotype Chow; ††P < 0.05 vs. genotype chF; †††P < 0.05 vs. wild-type on respective diet.
decreased ~2.4-fold in response to the cHF diet, while n-3 LC-PUFAs provided a partial protection from this decrease (Fig. 2E). A similar pattern of changes in the glycerone synthesis rate in response to n-3 LC-PUFAs was observed when measured directly in the skeletal muscle (Fig. 2F). Thus, in accordance with the previous study (26), the results of clamp studies suggested impairment of insulin sensitivity in response to whole-body ablation of AMPKα2 in Chow-fed mice. However, AMPKα2−/− mice seemed to be partially protected against cHF-induced insulin resistance, while AMPKα2 was required for preservation of insulin sensitivity in the skeletal muscle and especially in the liver in response to n-3 LC-PUFA feeding.

**Unmasking the role of AMPKα2 in the lipid-lowering effect of n-3 LC-PUFAs under hyperinsulinemic-euglycemic conditions.** In addition to the ad libitum-fed mice (Table 1), plasma lipid levels were also measured in fasted mice, as well as in mice subjected to hyperinsulinemic-euglycemic clamp (supplementary Table 2). In contrast to the ad libitum-fed state, cHF+F diet did not affect either triglyceride or NEFA levels under fasting conditions. Under the hyperinsulinemic-euglycemic conditions, both triglyceride and NEFA levels were lower in the cHF+F-fed than in the cHF-fed wild-type mice (~1.6-fold and ~1.4-fold difference, respectively), but no such difference between the diets was observed in AMPKα2−/− mice. Cholesterol levels were consistently decreased by n-3 LC-PUFAs independently of the metabolic state and genotype (supplementary Table 2).

In ad libitum-fed mice of both genotypes, the hepatic triglyceride content was increased ~twofold by cHF compared with the Chow diet, while triglyceride accumulation was increased only ~1.3-fold by cHF+F diet in both genotypes, documenting a protection against hepatic triglyceride accumulation by n-3 LC-PUFAs (Fig. 3A). Under hyperinsulinemic-euglycemic conditions, n-3 LC-PUFAs also protected livers of wild-type mice against the cHF-induced accumulation of triglycerides. However, this effect was absent in AMPKα2−/− mice (Fig. 3B). Moreover, a strong correlation was found between plasma NEFA levels and hepatic triglyceride content assessed under the clamp conditions in the cHF+F-fed AMPKα2−/− mice ($R^2 = 0.43, P < 0.05$) but not in wild-type mice ($R^2 = 0.08, P = 0.40$).

**Dietary n-3 LC-PUFAs increase 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside–stimulated fatty acid oxidation and insulin-stimulated lipogenesis in cultured hepatocytes from wild-type but not from AMPKα2−/− mice.** We sought to determine whether the differential effect of n-3 LC-PUFAs on accumulation of liver triglycerides in wild-type and AMPKα2−/− mice under the clamp conditions could be explained by hepatic lipid metabolism. In cultured hepatocytes isolated from mice following the different dietary treatments, activities of both fatty acid oxidation and de novo fatty acid synthesis were evaluated. The stimulatory effects of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR), an AMPK activator, and insulin on fatty acid oxidation and synthesis are shown in Fig. 4A and B, respectively (for corresponding basal metabolic activities, see supplementary Table 3, available in an online appendix). In hepatocytes from both Chow and cHF diet-fed mice, the absence of AMPKα2 was associated with a trend for lower AICAR-stimulated fatty acid oxidation. Although hepatocytes
from cHF-fed mice showed reduced stimulatory effect of AICAR irrespective of the genotype, cHF+F feeding normalized this defect in wild-type but not in AMPKα2−/− hepatocytes (Fig. 5A), suggesting AMPK-dependent induction of capacity for fatty acid oxidation by n-3 LC-PUFAs in the liver. The stimulatory effect of insulin on de novo fatty acid synthesis was reduced in hepatocytes from cHF-fed wild-type mice, whereas it was retained in the hepatocytes from cHF-fed AMPKα2−/− mice (Fig. 4B). cHF+F feeding tended to restore the stimulatory effect of insulin only in wild-type hepatocytes (Fig. 4B).

To further characterize hepatic effects of differential dietary treatment, the expression of selected genes was quantified in total RNA isolated from the livers of mice subjected to hyperinsulinemic-euglycemic clamp (Fig. 4C and D). Feeding cHF diet suppressed expression of lipogenic genes stearoyl-CoA desaturase (SCD-1) and SREBP-1c in all groups (except for SREBP-1c in AMPKα2−/− mice). This suppression was partially counteracted by cHF+F diet in wild-type but not AMPKα2−/− mice (Fig. 4C and D). Together with the de novo fatty acid synthesis data, these results further support the AMPKα2-dependent improvement of liver insulin sensitivity by n-3 LC-PUFAs.

Changes in hepatic diacylglycerol levels are associated with insulin-sensitizing effects of n-3 LC-PUFAs. To identify factors predisposing animals to insulin resistance in an AMPKα2-dependent manner, a detailed analysis of hepatic lipids in ad libitum-fed mice was performed. No major genotype-dependent differences in the contents of either ceramides or phospholipids were observed (supplementary Table 4). In contrast, hepatic content of diacylglycerols was affected in a genotype- and diet-dependent manner (Fig. 5A). Wild-type mice fed the cHF+F diet had lower diacylglycerol content than genotype-matched cHF diet-fed mice, while this effect of the cHF+F diet was not observed in AMPKα2−/− mice. Moreover, the analysis of fatty acid composition of the diacylglycerol fraction in the liver revealed that wild-type as well as AMPKα2−/− mice fed cHF diet were characterized by marked increase in the level of PUFAs but not monounsaturated or saturated fatty acids (Fig. 5B, C, and D and supplementary Table 4). The increase in the PUFAs content tended to be smaller in the wild-type compared with AMPKα2−/− mice (~1.7-fold and ~2.2-fold, respectively). Administration of n-3 LC-PUFAs completely prevented accumulation of hepatic polyunsaturated diacylglycerols in wild-type mice, whereas their level in the AMPKα2−/− animals, although decreased, was still significantly higher compared with genotype-matched Chow-fed mice (Fig. 5B). Regarding polyunsaturated diacylglycerols, α-linolenic acid (18:3n-3) appeared to be by far the most differentially regulated PUFAs in the diacylglycerol fraction in the two genotypes (supplementary Table 4). In addition, cHF+F diet markedly reduced hepatic content of mono-unsaturated diacylglycerols in wild-type but not in knockout animals (Fig. 5C). Hepatic diacylglycerol levels and their fatty acid composition were also analyzed in mice subjected to hyperinsulinemic-euglycemic clamp (supplementary Table 5 and supplementary Fig. 3). No significant differences among the groups were observed in total diacylglycerols content or in their saturated or monounsaturated fatty acid fractions (supplementary Fig. 3).

DISCUSSION

Previous animal studies demonstrated that n-3 LC-PUFAs could counteract the development of both hepatic steatosis (8,18,36,37) and hepatic insulin resistance (8,9,16), while suppressing lipogenesis and augmenting lipid catabolism in the liver (8,13,19,21). Using mice with a whole-body deletion of AMPKα2 and high-fat feeding, we show for the first time that AMPKα2 is required for the effect of n-3 LC-PUFAs to preserve whole-body, muscle, and especially hepatic insulin sensitivity, as well as to suppress hepatic and plasma triglycerides as well as NEFA levels under hyperinsulinemic-euglycemic clamp conditions. In contrast, AMPKα2 was not required for protection by n-3 LC-PUFAs from hepatic lipid accumulation and dyslipidemia in ad libitum-fed mice.

In addition to AMPKα2, PPARα was previously identified as an important determinant of n-3 LC-PUFAs’s effect on lipid metabolism, especially short-term modulation of hepatic gene expression (14) and insulin sensitivity (16). Thus, the reduction in hepatic triglyceride concentrations by fish oil feeding did not rescue insulin action in PPARα-null mice, while hepatic diacylglycerol concentrations were decreased by fish oil in a PPARα-dependent manner
and were associated with a preserved hepatic insulin sensitivity (16). It is generally accepted that 1) diacylglycerols rather than triglycerides or ceramides mediate hepatic insulin resistance in mice fed a high-fat diet (19,38,39), 2) diacylglycerol-induced insulin resistance depends on activation of protein kinase C, and 3) that polyunsaturated diacylglycerols in particular are better protein kinase C activators than saturated diacylglycerol species [reviewed in refs (38,39)]. Also our results showed that cHF diet-induced insulin resistance was associated primarily with the accumulation of PUFA in hepatic diacylglycerols and that n-3 LC-PUFA completely prevented cHF diet-induced increase in PUFA diacylglycerols in wild-type mice, whereas in AMPKα2/− animals, the content of these lipids was still significantly higher compared with the control. Moreover, it was only in ad libitum-fed mice but not in mice subjected to hyperinsulinemic-euglycemic clamps that the levels of hepatic diacylglycerols and their fatty acid compositions were associated with hepatic insulin sensitivity. It is possible that under clamp conditions AMPKα2-dependent effects of n-3 LC-PUFAs on liver diacylglycerols were masked by metabolic changes occurring during a 3-h infusion of insulin and glucose.

The failure of n-3 LC-PUFAs to decrease hepatic lipids in AMPKα2/− mice under clamp conditions could be due to primary alterations in metabolic fluxes in the liver, reflecting 1) increased de novo fatty acid synthesis, 2) decreased secretion of VLDL triglycerides, or 3) reduced fatty acid oxidation. De novo fatty acid synthesis was not the responsible factor, because hepatocytes of the n-3 LC-PUFA-fed AMPKα2/− mice showed decreased insulin-stimulated de novo fatty acid synthesis and reduced expression of SREBP-1c and SCD-1, as compared with hepatocytes isolated from n-3 LC-PUFA-fed wild-type mice, reflecting probably low insulin sensitivity of the liver in AMPKα2/− mice. Moreover, AICAR-stimulated fatty acid oxidation in hepatocytes from n-3 LC-PUFA-fed AMPKα2/− mice was markedly reduced as compared with those from wild-type mice, suggesting decreased hepatic capacity for fatty acid oxidation in the absence of AMPKα2, which could contribute to enhanced lipid accumulation. Therefore, these experiments supported a major role of hepatic AMPKα2 in the regulation of both insulin sensitivity and lipid metabolism by n-3 LC-PUFAs. However, the differential modulation of lipid accumulation by n-3 LC-PUFAs in the livers of wild-type and AMPKα2/−

![Graphs showing the effects of dietary treatment on lipid metabolism](https://example.com/graph.png)
mice under clamp conditions could also be secondary to the AMPKα2-dependent effects of n-3 LC-PUFAs in other tissues, resulting in a relatively high hepatic uptake of circulating NEFA in AMPKα2−/− mice. This is supported by persistently elevated plasma levels of NEFA in AMPKα2−/− mice, as well as by a significant correlation between plasma NEFA levels and hepatic triglyceride content observed under clamp conditions in AMPKα2−/− but not wild-type mice fed n-3 LC-PUFA-containing diet. Moreover, it has been shown in humans with nonalcoholic fatty liver disease that most of hepatic triglycerides arise from circulating NEFA (40). That plasma NEFA levels under clamp conditions were reduced only in wild-type but not in AMPKα2−/− mice fed n-3 LC-PUFAs may reflect a role of AMPKα2 in muscle lipid uptake mediated by lipoprotein lipase (41), as well as the antilipolytic effect of AMPK in adipose tissue, documented for AMPKα1 (42). In any case, decreased fatty acid oxidation in situ in the liver and, possibly even more importantly, abundant supply of circulating NEFA could be responsible for the lack of the antisteatotic effect of n-3 LC-PUFAs in AMPKα2−/− mice under clamp conditions (Fig. 6).

Previous studies reported contradictory results, showing either 1) activation of AMPK in rat liver (22) and murine adipose tissue (24) or 2) no changes in AMPK activity in the liver, skeletal muscle, and heart of mice (43) in response to dietary n-3 LC-PUFAs. These discrepancies could be related to differences in dietary n-3 LC-PUFA intake, nutritional state of animals, and other parameters. In accordance with the involvement of AMPKα2 in various effects of n-3 LC-PUFAs, our results document activation of AMPKα2 (but not AMPKα1) in the liver of mice by long-term n-3 LC-PUFA treatment, in the absence of significant changes in either the AMP to ATP ratio assessed in whole liver extracts (not shown and ref (44)) or the phosphorylation status of LKB1, an upstream kinase for AMPK (not shown and ref (45)). In addition, no effect on AMPK activity in either cultured hepatocytes (21) or embryonic kidney cells (not shown) of n-3 LC-PUFAs added to the cell culture medium could be detected. Therefore, the activation of AMPKα2 by n-3 LC-PUFAs probably does not depend on a direct interaction between n-3 LC-PUFAs and AMPK. On the other hand, induction of adiponectin by n-3 LC-PUFAs [results of this study and refs (46,47)] could be involved, because adiponectin activates AMPK in both the liver and skeletal muscle (35). Adiponectin is also required for the activation of AMPK upon administration of PPARγ agonists thiazolidinedi-
TG, triglycerides. Persisting elevated NEFA levels in circulation and thus better substrate availability in AMPK hepatic triglyceride content is markedly elevated despite reduced rates of de novo fatty acid synthesis. This effect could be secondary to capacity of hepatocytes to oxidize fatty acids in wild-type (left panels) but not in AMPK mice (right panels). When insulin and glucose levels are high, such as during hyperinsulinemic-euglycemic clamp, wild-type mice fed n-3 LC-PUFAs exhibit improved hepatic insulin sensitivity and decreased plasma levels of NEFAs as compared with high-fat diet-fed controls. This is associated with increased expression of lipogenic genes such as SREBP-1c and SCD-1 and increased drive for de novo fatty acid synthesis. Despite the elevated lipogenic drive under clamp conditions, the livers of wild-type mice fed n-3 LC-PUFAs show reduced accumulation of triglycerides. However, in AMPK mice fed n-3 LC-PUFAs, hepatic triglyceride content is markedly elevated despite reduced rates of de novo fatty acid synthesis. This effect could be secondary to persisting elevated NEFA levels in circulation and thus better substrate availability in AMPK mice under clamp conditions. FA, fatty acids; TG, triglycerides.

AMPKα1 and AMPKα2 contribute equally to total AMPK activity in the liver (50). In mice with liver-specific ablation of AMPKα2 (27), hepatic AMPKα2 was essential for suppressing hepatic glucose production and maintaining fasting blood glucose levels; however, the absence of AMPKα2 did not affect inhibitory action of insulin on hepatic glucose production. In our study, although fasting blood glucose levels were unaltered by whole-body ablation of AMPKα2, the beneficial effect of dietary n-3 LC-PUFAs on hepatic insulin sensitivity was clearly AMPKα2-dependent. Differential regulation of glucose homeostasis in the above transgenic models likely reflects the complexity of whole-body (26) versus liver-specific (27) deletion of AMPKα2. In contrast to the previous report, showing induction of adiposity and adipocyte hypertrophy in AMPKα2−/− mice fed a lard-based high-fat diet (49), our study documented a relatively low weight gain, low adiposity, and smaller fat cells in AMPKα2−/− mice fed a corn-oil based high-fat diet. This discrepancy could be related to the differences in the composition of experimental high-fat diets; however, our results are consistent with the elevated sympathetic tonus of AMPKα2−/− mice (26), which may stimulate energy dissipation in these animals. In any case, lower body weight of cHF-fed AMPKα2−/− mice as compared with their wild-type counterparts could be related to better insulin sensitivity of the former mice, as suggested by the differences in insulinemia, results of hyperinsulinemic-euglycemic clamp, stimulatory effect of insulin on lipogenesis, and expression of lipogenic genes in the liver.

In conclusion, the preservation of hepatic insulin sensitivity by n-3 LC-PUFAs in mice fed a high-fat diet depends on AMPKα2. The accumulation of diacylglycerols, which is regulated in an AMPKα2-dependent manner, could contribute to the modulation of hepatic insulin sensitivity in response to dietary n-3 LC-PUFAs. On the other hand, the AMPKα2-dependent acute changes in lipid metabolism and hepatic triglyceride accumulation, which are unmasked under insulin-stimulated conditions such as during hyperinsulinemic-euglycemic clamp, largely reflect the extrahepatic action of n-3 LC-PUFAs. Our results are relevant for the development of novel strategies for prevention and treatment of the metabolic syndrome.

ACKNOWLEDGMENTS
This study was supported by grants from the Czech Science Foundation (301/10/1420) and the Ministry of Education, Youth and Sports (1M6837805002, COST BMB0602-OC08007) of the Czech Republic. Further sup-
port included grants from the European Commission (LSHM-CT-2004-005272, EXGENESIS) and from EPAX AS (Norway), as well as the research project AVOZ50110509. No other potential conflicts of interest relevant to this article were reported.

T.J. and M.R. performed experiments and wrote the manuscript. O.K., Z.M.J., D.M., V.K., M.H., and P.J. performed experiments. I.M. quantified tissue nucleotides. M.B. performed analysis of hepatic lipids and contributed to discussion. J.G. performed analysis of hepatic lipids. S.H. contributed to experiments on kidney cells. B.V. developed AMPK \(^{2/−}\) mouse model to the Prague laboratory and contributed to discussion. S.H. performed experiments on kidney cells. B.V. developed AMPK \(^{2/−}\) mice and contributed to discussion. J.K. wrote the manuscript.

The authors thank D. Grahame Hardie for the sheep AMPK \(^{1}\) and AMPK \(^{2}\) antibodies, Z. Szulc for the gift of \(N\)-palmitoyl-D-erythrylo-sphingosine (C17 base), and J. Jones (NMR Research Unit, Department of Biochemistry and Center for Neurosciences and Cell Biology, University of Coimbra, Coimbra, Portugal) for critical reading of the manuscript.

The manuscript included grants from the European Commission (LSHM-CT-2004-005272, EXGENESIS) and from EPAX AS (Norway), as well as the research project AVOZ50110509. No other potential conflicts of interest relevant to this article were reported.

T.J. and M.R. performed experiments and wrote the manuscript. O.K., Z.M.J., D.M., V.K., M.H., and P.J. performed experiments. I.M. quantified tissue nucleotides. M.B. performed analysis of hepatic lipids and contributed to discussion. J.G. performed analysis of hepatic lipids. S.H. contributed to experiments on kidney cells. B.V. developed AMPK \(^{2/−}\) mouse model to the Prague laboratory and contributed to discussion. S.H. performed experiments on kidney cells. B.V. developed AMPK \(^{2/−}\) mice and contributed to discussion. J.K. wrote the manuscript.

The authors thank D. Grahame Hardie for the sheep AMPK \(^{1}\) and AMPK \(^{2}\) antibodies, Z. Szulc for the gift of \(N\)-palmitoyl-D-erythrylo-sphingosine (C17 base), and J. Jones (NMR Research Unit, Department of Biochemistry and Center for Neurosciences and Cell Biology, University of Coimbra, Coimbra, Portugal) for critical reading of the manuscript.
Carling D, Kimura S, Nagai R, Kahn BB, Kadouwki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288–1295

36. Kajikawa S, Hanada T, Kawashima A, Inoda K, Mizuguchi K. Highly purified eicosapentaenoic acid prevents the progression of hepatic steatosis by repressing monounsaturated fatty acid synthesis in high-fat/high-sucrose diet-fed mice. Prostaglandins Leukot Essent Fatty Acids 2009;80(4):229–238

37. Uyeda K, Repa JJ. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab 2006;4:107–110

38. Wakelam MJO. Diacylglycerol—when is it an intracellular messenger? BBA-Mol Cell Biol Lipids 1998;1436:117–126

39. Schmitz-Peiffer C, Biden TJ. Protein kinase C function in muscle, liver, and beta-cells and its therapeutic implications for type 2 diabetes. Diabetes 2008;57:1774–1783

40. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343–1351

41. Ohira M, Miyashita Y, Murano T, Watanabe F, Shirai K. Metformin promotes induction of lipoprotein lipase in skeletal muscle through activation of adenosine monophosphate-activated protein kinase. Metabolism 2009;58:1408–1414

42. Daval M, Diot-Dupuy F, Bazin R, Hainault I, Viollet B, Vaquont S, Hajihuch E, Ferré P, Foufelle F. Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J Biol Chem 2005;280:25250–25257

43. Dobrzyn A, Dobrzyn P, Miyazaki M, Ntambi JM. Polyunsaturated fatty acids do not activate AMP-activated protein kinase in mouse tissues. Biochem Biophys Res Commun 2005;332:892–896

44. Salati LM, Clarke SD. Fatty acid inhibition of hormonal induction of acetyl-coenzyme A carboxylase in hepatocyte monolayers. Arch Biochem Biophys 1986;246:82–89

45. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlatter U, Walliman T, Carlson M, Carling D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003;13:2004–2008

46. Flachs P, Mohamed-Ali V, Horakova O, Rossmeisl M, Hosseinizadeh-Attar MJ, Hensler M, Ruzickova J, Kopecky J. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 2006;49:394–397

47. Itoh M, Suganami T, Satoh N, Tanimoto-Koyama K, Yuan X, Tanaka M, Kawano H, Yano T, Aoe S, Takoya M, Shimatsu A, Kuzuya H, Kamei Y, Ogawa Y. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol 2007;27:1918–1925

48. Navrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, Pang Z, Chen AS, Ruderman NB, Chen H, Rossetti L, Scherer PE. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2006;281:2654–2660

49. Villena JA, Viollet B, Andreelli F, Kahn A, Vaquont S, Sul HS. Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-alpha2 subunit. Diabetes 2004;53:2242–2249

50. Cheung PC, Salt IP, Davies SP, Hardie DG, Carling D. Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J 2000;346:659–669